Abstract Library

#4659 Current role of systemic lanreotide therapy of patients with advanced, unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) sporadic and hereditary

Introduction: Retrospective, performed in prospective manner single-arm, open-label, case series study to assess the efficacy of lanreotide in patients with unresectable, non-metastatic paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations.

Conference:

Presenting Author:

Authors: Kolasińska-Ćwikla A, Pęczkowska M, Michałowska I, Pałucki J, Roszkowska-Purska K,

Keywords: Paraganglioma / pheochromocytoma (PPGL) spontaneous or germline mutations, Lanreotide therapy, fractionated metoxycatecholamines,

#4626 Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Introduction: The efficacy and time to progression (TTP) following peptide receptor radionuclide therapy (PRRT) for pancreatic neuroendocrine tumours varies widely.

Conference:

Presenting Author: Papantoniou D

Authors: Tiensuu Janson E, Fröss-Baron K, Grönberg M, Ziolkowska B,

Keywords: prrt, pancreatic neuroendocrine tumour, predictive model,

#4305 Lower dose of lenvatinib is similarly effective as higher dose for patients (pts) with advanced neuroendocrine tumours (NETs): A multinational retrospective cohort

Introduction: A phase II trial with lenvatinib 24mg PO daily was effective for pts with gastroenteropancreatic (GEP) NETs but led to significant toxicity. In clinical practice, dose reductions are commonly required.

Conference:

Presenting Author: Riechelmann R

Authors: Zanetta G, Grozinsky-Glasberg S, Bel-Ange A, Barros M, Felismino T,

Keywords: lenvatinib, neuroendocrine tumour, dose optimisation, toxicity,

#4230 Grade ≥3 subacute haematological toxicity with 177Lu-DOTATATE PRRT – Results from LUMEN study

Introduction: Bone marrow toxicity during peptide receptor radionuclide therapy (PRRT), results from radiation damage to haematopoietic tissue. Prospective comprehensive data on subacute haematological toxicity are scarce.

Conference:

Presenting Author: Mileva M

Authors: Mileva M, van Bogaert C, Ameye L, Flamen P, Karfis I,

Keywords: peptide receptor radionuclide therapy, GEP-NET, haematological toxicity,

#4161 177Lu-DOTATATE (177Lu) efficacy in metastatic well-differentiated neuroendocrine tumors (wdNET): Differences in response according to metastases (met) location

Introduction: Treatment with 177Lu is standard of care for wdNET with high somatostatin receptor expression. Patterns of response could differ between hepatic (hep) and extrahepatic (ehep) met.

Conference:

Presenting Author:

Authors: Sánchez Gómez L, Guillén Sentís P, Ruffinelli J, Torrent F, Vercher Conejero J,

Keywords: 177lu-dotatate, well-differentiated neuroendocrine tumor, tumor growth rate,